Background: Effects of statin therapy on cardiac sympathetic nerve activity in patients with chronic heart failure (CHF) have not previously been evaluated.
etrospective analyses have shown that statin therapy may have a beneficial effect in patients with chronic heart failure (CHF). 1-3 However, recent prospective studies using hydrophilic rosuvastatin have not shown any beneficial effect on mortality. 4, 5 Metabolic and cardiac effects may differ between the lipophilic and hydrophilic statins. Gao et al reported that lipophilic simvastatin therapy in pacing-induced CHF inhibited NADPH oxidative activity in the rostral ventrolateral medulla and reduced central sympathoexcitatory response in association with improvement in left ventricular (LV) function. 6 However, there has not been any report about differences between the effects of lipophilic statins and hydrophilic statins on cardiac sympathetic nerve activity in CHF patients with dilated cardiomyopathy (DCM).
Activation of the sympathetic nerve system is one of the important prognostic predictors for CHF patients. 7, 8 Cardiac imaging with 123 I-metaiodobenzylguanidine (MIBG), an analog of norepinephrine, is a useful tool for detecting abnormalities of myocardial sympathetic nerve activity and predicting mortality in patients with CHF. 9- 13 In addition, plasma levels of B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are well-established, powerful risk markers in CHF. 14- 17 The present study evaluated the comparative effects of lipophilic atorvastatin and hydrophilic rosuvastatin on cardiac sympathetic nerve activity evaluated by MIBG parameters and plasma NT-proBNP in CHF patients with DCM who have already received standard HF therapy.
Methods

Patients
The subjects were 63 stable DCM outpatients who had al-Statins and Cardiac Nervous Activity in CHF ready received standard therapy for more than 6 months. The diagnosis of DCM was based on patient history, physical examination, electrocardiography, chest radiology, echocardiography, left ventriculography coronary angiography and endomyocardial biopsy. Endomyocardial biopsies were obtained to rule out secondary cardiomyopathies caused by viral or other infectious myocarditis, sarcoidosis, amyloidosis or other metabolic heart diseases. In this study, patients with DCM were defined as those had previously been admitted to hospital for management of CHF caused by systolic HF, which was defined as LV ejection fraction (LVEF) <45% at the initial diagnosis by 2-dimensional echocardiography or ventriculography using contrast medium or radioisotope. We excluded patients with renal failure (serum creatinine >2.0 mg/dl), diabetes mellitus, chronic inflammatory disease or malignancy. Informed consent was given by all patients before participation in the study, according to the protocol approved by the institutional Committee on Human Investigation.
Study Protocol
The 63 stable outpatients with DCM, who were already receiving standard therapy for CHF, were randomized to atorvastatin (5 mg/day, n=32) or rosuvastatin (2.5 mg/day, n=31) using the envelope method. Within 1 week of entry to the study, cardiac MIBG scintigraphy and echocardiography were performed and 6 months later, the same measurements were obtained. None of the patients had a cardiovascular event during the follow-up period. Physicians were blind to the values of MIBG and echocardiographic parameters and to the plasma levels of biochemical markers until the completion of the study. Blood samples were drawn from the antecubital vein after at least 30 min of supine bed rest, and the LVEF was measured by the biplane disc summation method on echocardiography (Simpson's rule) before and after 6 months of atorvastatin or rosuvastatin treatment. The plasma levels of NT-proBNP, oxidized low-density lipoprotein (oxLDL) and high-sensitivity C-reactive protein (hsCRP), and serum total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and creatinine were determined before and after 6 months of treatment with the statins.
MIBG Imaging
All patients were injected intravenously with 3 mCi of 123 I-MIBG. Images were obtained using a single-head gamma camera with a low-energy collimator (Toshiba GCA-901A). Energy discrimination was provided by a 20% window centered on the 159 KeV photopeak. A 5-min static acquisition HR, heart rate; SBP, systolic blood pressure; LVDd, left ventricular diastolic diameter; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; oxLDL, oxidized LDL; MIBG, metaiodobenzylguanidine; H/M, heart/mediastinum count; WR, washout rate; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker. TSUTAMOTO T et al.
was performed at 15 min (early) and 180 min (delayed) after radioisotope injection as previously reported. 11 On the anterior planar image, a region of interest (ROI) was manually placed over the heart and another ROI was placed over the upper mediastinal area. Using early and delayed images, the heart to mediastinum (H/M) ratio and the washout rate (WR) were calculated from the average counts in each ROI by 2 independent observers. The WR was defined as the percentage change in cardiac activity (H) from early to delayed images within the LV area as follows:
early × 100(%). Decay correction was not applied. Assessment was done in a blinded fashion by 2 independent observers with no knowledge of the clinical status or medical therapy of each patient. Interobserver differences in the H/M ratio (delayed) and WR were not significant. In our laboratory, the normal values of the H/M ratio (delayed) and WR were 2.60±0.24 and 28.0±3.1%, respectively. 11
Measurement of oxLDL, NT-ProBNP and hsCRP
Blood for measurement of the plasma level of oxLDL, a marker of oxidative stress, was placed into a plain tube, centrifuged at 3,000 rpm for 15 min at 4°C before a specific immunoradiometric assay using a commercial kit (Kyowa Medex, Tokyo, Japan), as previously reported. 18 Plasma levels of NT-proBNP concentrations were measured using the Elecsys proBNP sandwich immunoassay (Roche Diagnostics, Basel, Switzerland) as previously reported. 16 Blood for measurement of the serum level of hsCRP was transferred to a chilled tube, then centrifuged at 3,000 rpm for 15 min at 4°C, and the serum thus obtained was stored at -30°C until sensitive nephelometric assay (Behring Diagnostics, Marburg, Germany) performed as previously reported. 19
Statistical Analysis
All results are expressed as the mean ± SD. Categorical data were compared by chi-square distribution. Univariate analysis was performed using Student's t-test. Data obtained after rosuvastatin therapy were compared with those after atorvastatin therapy using ANOVA. Because BNP and hsCRP levels were not normally distributed, differences between the groups were analyzed by Mann-Whitney U-test and differences in mean levels of these before and after administration of atorvastatin or rosuvastatin were tested by nonparametric Wilcoxon rank-sum test for paired values. Pearson's correlation coefficient was used to determine correlations and regression analysis. A 2-tailed probability value of 0.05 was considered significant. P<0.05 was regarded as significant.
Results
Patients' Characteristics
There was no difference in the baseline characteristics of the 2 treatment groups ( Table 1) . At entry into the study, most patients were receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and β-blockers. There was no difference between the 2 groups in either the MIBG parameters or baseline biomarkers such as the lipid profile and NT-proBNP, hsCRP and oxLDL levels.
Comparison of 123 I-MIBG Findings Before and After Treatment Randomization
In patients receiving rosuvastatin, neither the H/M ratio (2.26±0.5 vs. 2.25±0.5, P=0.701) nor the WR (31.3±7.3 vs. 31.1±6.1%, P=0.343) was changed after 6 months compared with baseline values (Figure 1) . In contrast, patients receiving atorvastatin demonstrated a significant increase in H/M ratio (2.18±0.4 vs. 2.36±0.4, P<0.0001), and the WR was significantly decreased (34.8±5.7 vs. 32.6±6.3 %, P=0.0001) after 6 months compared with the baseline value (Figure 2) .
Comparison of Clinical and Biochemical Markers Before and After Treatment Randomization (Table 2)
In both groups, the plasma norepinephrine level did not change and serum levels of total cholesterol, triglyceride and LDL cholesterol were significantly decreased after 6 months compared with the baseline value ( Table 2) . LVEF was significantly improved in the atorvastatin group (42.8±9.6 vs. 44.3±9.6%, P=0.0029 within group, P=0.025 with ANOVA) but not in the rosuvastatin group (Figure 3) . Plasma levels of NT-proBNP (729±858 vs. 558±747 pg/ml, P=0.0139 within group, P=0.0046 with ANOVA) and oxLDL (9.7±4.4 vs. 7.7± 3.6 unit/ml, P=0.001 within group, P=0.045 with ANOVA) were significantly decreased in the atorvastatin group but not in the rosuvastatin group (Figure 3) . Plasma levels of hsCRP were slightly decreased in the atorvastatin group compared with the rosuvastatin group (P=0.07 with ANOVA). 
Correlation Between Changes in oxLDL and Changes in H/M Ratio and LVEF in DCM Patients Receiving Atorvastatin
In patients receiving atorvastatin, there was a negative correlation between the ∆ change of oxLDL (oxLDL after 6 monthsoxLDL at baseline) and the ∆ change of H/M (H/M after 6 months -H/M at baseline) (r=-0.420, P=0.0168) and the ∆ change of LVEF (LVEF after 6 months -LVEF at baseline) (r=-0.465, P=0.0074) (Figure 4) .
Discussion
In the present study, both the lipophilic atorvastatin and the hydrophilic rosuvastatin decreased LDL cholesterol to the same degree in patients with non-ischemic DCM who were already receiving standard therapy for CHF. We further found that (1) atorvastatin but not rosuvastatin can improve the cardiac 123 I-MIBG imaging parameters, decrease the plasma levels of NT-proBNP and oxLDL and improve LVEF, and (2) in the atorvastatin group, changes in plasma oxLDL, a biomarker of oxidative stress, significantly correlated with changes in LVEF and the H/M ratio. As NT-proBNP and the parameters of cardiac 123 I-MIBG imaging are powerful prognostic predictors, 9-13,16,17,20-24 our findings suggest the superiority of lipophilic atorvastatin to hydrophilic rosuvastatin for the management of CHF caused by DCM. Serial cardiac 123 I-MIBG imaging and measurement of plasma NT-proBNP concentration had an especially great impact on prognosis, 11,23,24 indicating the beneficial effects of atorvas- . Correlation between ∆ change in oxLDL (oxLDL after 6 months - oxLDL at baseline) and (A) ∆ change in LVEF (LVEF after 6 months - LVEF at baseline) and (B) ∆ change in H/M ratio (H/M ratio after 6 months - H/M ratio at baseline) in patients receiving atorvastatin. LVEF, left ventricular ejection fraction; H/M, heart to mediastinum; oxLDL, oxidized low-density lipoprotein. Statins and Cardiac Nervous Activity in CHF tatin therapy in DCM patients. Although recent prospective studies (CORONA, GISSI-HF) 4,5 using hydrophilic rosuvastatin showed no beneficial effect on mortality, Vrtovec et al reported that atorvastatin therapy reduced the incidence of sudden cardiac death in patients with advanced CHF. 25 As cardiac 123 I-MIBG imaging may predict sudden death in patients with CHF, 26 our findings of improvement in cardiac 123 I-MIBG imaging may support the underlying mechanism described by Vrtovec et al. 25 Regarding the effects of statins on LVEF, Krum et al reported that hydrophilic rosuvastatin therapy had no effect on LVEF, 27 which is consistent with our findings. Several studies have reported that lipophilic atorvastatin therapy induced a significant increase in LVEF. [28] [29] [30] In addition, lipophilic atorvastatin and simvastatin have been shown to increase LVEF and decrease the BNP level, 31,32 which is also consistent with our findings. In an ischemia-induced myocardial stunning model, Ichihara et al 33 reported that lipophilic statins decreased LVEF after reperfusion partly because of a decrease in cardiac CoQ10. The reason why LVEF increased after lipophilic atorvastatin therapy in patients with DCM remains uncertain.
Oxidative stress plays an important role in LV function and we have reported that the transcardiac gradient of oxLDL may be a marker of oxidative stress in the heart and that in patients with DCM the LV dysfunction may be partly caused by oxidative stress. 18 Moreover, the plasma oxLDL level, a biomarker of oxidative stress in the failing heart, is an independent prognostic predictor in CHF patients. 34 The fact that lipophilic atorvastatin but not hydrophilic rosuvastatin decreased oxLDL is an interesting finding from the present study, because previous experimental 6,35, 36 and clinical studies 37,38 suggested that lipophilic statins improve cardiac sympathetic activity by reducing oxidative stress. Mason et al reported that the antioxidant effects of an active metabolite of atorvastatin were stronger than those of rosuvastatin, 39 which is consistent with the present findings. Therefore, the significant increase in LVEF observed in our study may be partly related to an improvement of the oxidative stress in the myocardium following atorvastatin administration.
Metabolic effects, including the insulin sensitivity, of lipophilic and hydrophilic statins may differ in patients with hypercholesterolemia and type 2 diabetes mellitus. We recently reported that hydrophilic rosuvastatin but not lipophilic simvastatin increased adiponectin and decreased glycated hemoglobin levels in patients with non-ischemic CHF complicated by diabetes mellitus, 40 indicating that hydrophilic rosuvastatin treatment is more useful than lipophilic simvastatin for the management of CHF patients with diabetes mellitus. Based on all the findings, including those from the present study, further studies are recommended to clarify which statin, lipophilic or hydrophilic, is better for the overall management of CHF patients.
Study Limitations
Several limitations should be noted in the interpretation of these results. First, we excluded patients with diabetes mellitus and did not evaluate adiponectin and glycated hemoglobin levels, so the metabolic effects of statins were not evaluated in the present study. Second, most patients in the present study had mild CHF (NYHA functional class II), so our conclusions may be limited to such patients. Third, the doses of statins were relatively low but apparently effective in this population judging from the degree of decrease in LDL cholesterol. In addition, a relatively low dose of statin may have favorable effects on the prognosis for CHF patients. 41 Last, the small number of patients with nonischemic CHF and the open-trial methodology (not double-blinded study) were limitations.
Conclusions
Atorvastatin but not rosuvastatin improved cardiac sympathetic nerve activity, decreased plasma levels of NT-proBNP and oxLDL and improved LVEF, suggesting that lipophilic atorvastatin is more useful than hydrophilic rosuvastatin in the treatment of non-diabetic CHF patients with DCM.
